Uncategorized
Allegro initiates phase 2 study of vitreomacular traction therapy
Allegro Ophthalmics has initiated a phase 2 study of ALG-1001 in patients with vitreomacular traction, according to a press release.The placebo-controlled, randomized, double-masked, dose-ranging study will evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. The primary efficacy endpoint is release of VMT as determined by optical coherence tomography images. Secondary endpoints include the observation of nonsurgical closure of full-thickness macular holes, best corrected visual acuity improvement over baseline and forgone need for pars plana vitrectomy, according to the release.